These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32752001)

  • 1. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
    Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV Type 1 Integrase Natural Polymorphisms in Viral Variants Circulating in FSU Countries.
    Lapovok I; Laga V; Kazennova E; Bobkova M
    Curr HIV Res; 2017 Nov; 15(5):318-326. PubMed ID: 28814231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naïve HIV-1 Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Intervirology; 2017; 60(4):131-137. PubMed ID: 29212076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda.
    McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ
    AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Rinke de Wit TF; Paredes R
    J Antimicrob Chemother; 2018 May; 73(5):1167-1172. PubMed ID: 29462322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.
    Bailey AJ; Rhee SY; Shafer RW
    AIDS Res Hum Retroviruses; 2021 Oct; 37(10):736-743. PubMed ID: 33683148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.
    Madyadi A; Dhoro M; Shamu T; Washaya T; Kouamou V; Chimukangara B; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2021 Dec; 37(12):954-961. PubMed ID: 34714124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
    Low A; Prada N; Topper M; Vaida F; Castor D; Mohri H; Hazuda D; Muesing M; Markowitz M
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4275-82. PubMed ID: 19651917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).
    Yang Z; Yang X; Deng X; Wei S; Liu J; Ma J; Zhao Q; Huo Y
    Infection; 2021 Dec; 49(6):1195-1202. PubMed ID: 34279816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.
    Henerico S; Lyimo E; Makubi AN; Magesa D; Desderius B; Mueller A; Changalucha J; Kalluvya SE; Van Zyl G; Preiser W; Mshana SE; Kasang C
    J Antimicrob Chemother; 2022 Oct; 77(11):3138-3143. PubMed ID: 36101479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.
    Meixenberger K; Yousef KP; Smith MR; Somogyi S; Fiedler S; Bartmeyer B; Hamouda O; Bannert N; von Kleist M; Kücherer C
    Virol J; 2017 Nov; 14(1):223. PubMed ID: 29137637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naïve patients in South Sudan.
    Giovanetti M; Farcomeni S; Sernicola L; Virtuoso S; Fontanelli Sulekova L; Maggiorella MT; Buttò S; Taliani G; Ciccozzi M; Borsetti A
    J Med Virol; 2022 Jul; 94(7):3320-3327. PubMed ID: 35277871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.
    Wenk BM; Mbunkah HA; Nsanwe NN; Mbu ET; Besong LM; Sama BA; Orock E; Leemann C; Metzner KJ
    J Antimicrob Chemother; 2021 Jan; 76(1):124-129. PubMed ID: 32954411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.
    Sebastião CS; Abecasis AB; Jandondo D; Sebastião JMK; Vigário J; Comandante F; Pingarilho M; Pocongo B; Cassinela E; Gonçalves F; Gomes P; Giovanetti M; Francisco NM; Sacomboio E; Brito M; Neto de Vasconcelos J; Morais J; Pimentel V
    Sci Rep; 2024 Jul; 14(1):15893. PubMed ID: 38987263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Celera RUO integrase resistance assay across multiple HIV-1 subtypes.
    Wallis CL; Viana RV; Saravanan S; Silva de Jesus C; Zeh C; Halvas EK; Mellors JW
    J Virol Methods; 2017 Mar; 241():41-45. PubMed ID: 27993614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.